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Abstract 
Metastasis is the major cause of mortality in cancer 
disease and still constitutes one of the most controversial 
mechanism, not yet fully understood. What is almost 
beyond doubt is that circulatory system is crucial for 
cancer propagation. Regarding this system, much 
attention has been recently paid to liquid biopsy. This 
technique is aimed to detect circulating tumor cells (CTCs) 
and circulating nucleic acids so it can be used as a tool for 
diagnostic, prognostic and follow-up of patients. Whereas 
CTCs tend to be scarce in serum and plasma from cancer 
patient, abundant circulating nucleic acids can be detected 
in the same location. This fact, together with the genetic 
origin of cancer, stands out the relevance of circulating 
nucleic acids and shed light into the role of nucleic acids as 
drivers of metastasis, a recently discovered phenomenon 
called Genometastasis. This innovative theory supports 
the transfer of oncogenes from cancer cells to normal 
and susceptible cells located in distant target organs 
through circulatory system. What is more, many biological 
processes haven been described to deliver and secrete 
circulating nucleic acids into the circulation which can 
allow such horizontal transfer of oncogenes. In this 
review, we focus not only on these mechanisms but also 
we demonstrate its putative role in cancer propagation 
and give insights about possible therapeutic strategies 
based on this theory. Our objective is to demonstrate how 
findings about cell-to-cell communications and previous 
results can agree with this unprecedented theory.
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and genetic analysis of the whole tumor might be crucial 
during CRC follow-up. Similarly, tumor genotyping is also 
required in the case of anti-EGFR therapies, to which only 
the patients with KRAS wild-type gene respond. Thus, 
liquid biopsy can be conceived not only for recording 
tumor progression but also for selecting the most suitable 
treatment. 
As mentioned before, liquid biopsy can be intended 
to detect circulating tumor cells (CTCs) and/or circulating 
cfNA. 
CTCs
CTCs can be secreted into circulation by primary and 
metastatic tumor deposits. In 1869, during autopsy of 
a breast cancer patient, CTCs were first identified as 
cells similar to those of the primary tumor, presented 
in the bloodstream[4]. These cells are mainly found in 
patients with malignant diseases like carcinomas, being 
extremely rare in healthy subjects and patients with 
nonmalignant diseases[5]. 
CTCs can be difficult to obtain given its heterogeneous 
morphology and its limited amount in the circulation: 
They constitute one cell per 1 × 109 normal bloodstream 
cells in patients with metastatic cancer[6]. In other 
terms, in 7.5 mL of blood from metastatic carcinoma 
patients, only 5 to 50 CTCs are presented on average[7]. 
This small cell number makes it difficult to detect CTCs, 
especially small subpopulations of tumor cells, which 
can harbor crucial mutation for tumorigenesis. However, 
many attempts and approaches have been designed 
to isolate CTCs. Most of them are based on antibody 
identification of cell surface markers, such as EpCAM, 
or size differences between CTCs and the rest of blood 
cells[8]. Once CTCs are obtained, they have to be further 
analyzed through genome sequencing. Nevertheless, 
these isolating techniques might not provide the whole 
spectrum of CTCs, uncovering the tumor heterogeneity. 
As an example, basal-like breast cancer CTCs with low 
levels of EpCAM may not be captured using this cell 
surface marker determinant[7]. On the other hand, false-
positive CTC results can also be found in the case of 
patients with benign inflammatory disease such as Crohn 
disease. It has been shown that 11% to 19% of these 
patients present small numbers of circulating epithelial 
cells detectable that can be confused with CTCs[9]. In 
addition, although correlation between cell number and 
disease severity have been established in metastatic 
patients from breast, colon and prostate cancer[10-12], less 
is known about early-stage tumors and CTC number. 
Altogether, more studies are required to elucidate the 
relationship between tumor burden and the number 
of CTCs in order to verify the clinical utility of CTCs as 
prognostic markers[7]. 
It is also worth noting that CTCs are difficult to grow 
in culture, which questions the functionality of these 
cells. Thus, it can be hypothesized that these cells are 
more likely to constitute death cells, poured by tumor 
mass, than active cells responsible for metastasis em-
ergence. 
Core tip: Liquid biopsy not only constitutes a promising 
tool for cancer diagnostic and patient follow-up but 
also it may help in the comprehension of metastasis. 
This technique has revealed how circulating tumor cells 
are limited in blood, while circulating nucleic acids are 
much more abundant. This property, together with the 
demonstrated capability of circulating nucleic acids to 
transform susceptible cells, strongly support the theory 
of genometastasis. This theory sustains that cancer 
propagation relies on gene transfer from malignant cells 
to normal cells. We pretend to gather all these concepts, 
also including cell-to-cell communication mechanisms to 
demonstrate this phenomenon. 
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CONCEPT OF LIQUID BIOPSY
Liquid biopsy
Traditionally, tissue biopsy has been used to diagnose 
and manage diseases. In cancer, biopsies are used to 
determine histological properties of the tumor as well 
as its genetic profile for diagnostic, prognostic purposes 
and prediction of response to therapies. However, 
the characteristic heterogeneity of tumors makes it 
necessary to analyze different parts of the same tissue 
which results in repeated sampling. Obtaining several 
tissue biopsies involves a high risk for the patient as 
well as economic cost for the system. As an alternative 
to tissue biopsy, liquid biopsy constitutes a promising 
and less invasive technique. 
Liquid biopsy consists on the detection of cancer-
derived molecular biomarkers, such as tumor cells or 
cell-free nucleic acids (cfNA) in biological fluids, mainly 
in blood. Given the non-invasiveness properties of 
the technique, it is possible to take repeated samples 
and so, to follow the progression and evolution of the 
disease in contrast to the static image from tissue 
biopsy.
The effectiveness of this approach has been demon-
strated in different malignancies including breast, 
pancreatic and colorectal cancer (CRC)[1]. In the case 
of pancreatic cancer, liquid biopsy provides an ad-
vantageous technology regarding the anatomical and 
clinical difficulties for pancreatic tissue[2]. It would also 
help in the early detection of this disease, which is 
usually diagnosed at an advanced stage because it 
develops with no symptoms. For its part, CRC is mainly 
characterized by its heterogeneous genetic profile, in 
which new mutations constantly appear during tumor 
development[3]. These new mutations may confer 
proliferative capacities to tumor cells and, thus, molecular 
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Circulating nucleic acids
Regarding to circulating nucleic acids we can make a 
distinction between circulating cell-free DNA (cfDNA) 
and cell-free RNA (cfRNA). 
Circulating cfDNA: The first association between 
cancer and the presence of circulating cfDNA was 
established in 1977 by Leon et al[13] who detected a 
higher concentration of DNA in serum from cancer 
patients. Ten years later, Stroun et al[14] confirmed this 
relation by isolating and characterizing DNA obtained 
from the plasma of cancer patients. Moreover, it was 
further shown that patients with malignant tumors have 
higher circulating cfDNA levels than patients suffering 
benign disease[15]. The tumor origin of such cfDNA was 
also confirmed by the identification of tumor-specific 
abnormalities such as loss of heterozygosity (LOH) of 
microsatellites and methylation of CpG islands[16,17]. In 
addition from tumor cells, plasma cfDNA may come 
from blood cells and other tissue-specific cells. However, 
the proportion of DNA derived from different origins 
widely varies. In fact, circulating tumor DNA proportion 
range between 0.01% and 93% in cancer patients[7,18]. 
cfDNA is usually found in plasma as with a double-
stranded structure, although single-stranded circulating 
DNA has also been identified[19-21]. It should be noted 
that DNA molecule need to be protected by different 
complexes or other molecules, described in detail below, 
in order to avoid its degradation by serum nucleases. 
Circulating cfRNA: Circulating cfRNA was first isolated 
in 1987 from serum of patients with malignant disorders 
and culture media of different malignant cell lines. 
It was initially found in the form of RNA-proteolipid 
complex[22]. As it happens with DNA, it is no surprising 
to detect cfRNA associated with other molecules since it 
alone can be very labile due to the increased amounts 
of RNases present in the circulation. 
Circulating RNA consist of messenger RNA (mRNA) 
and microRNA (miRNA). Regarding to mRNA, different 
transcripts have been identified to be overexpressed 
in plasma of tumor patients, especially human tran-
scriptase reverse telomerase (hTERT) mRNA levels in 
malignancies such as breast cancer or colon cancer[23-25]. 
miRNA molecules are fragments of 19-25 bp non-coding 
RNA molecules which derive from 70-100 bp hairpin 
precursor molecules. By posttranscriptional regulation, 
they modulate the expression of target genes involved 
in many physiological and pathological process such 
as development, cell proliferation, differentiation or 
apoptosis[26,27]. 
Circulating nucleic acids as biomarkers: Although 
the term nucleic acids refers to both types of molecules, 
special attention has been paid to cfDNA in the field of 
liquid biopsy because it carries the tumor-associated 
mutations and thus, it represents an attractive bio-
marker. 
As commented before, circulating DNA gives more 
detailed information about the heterogeneity of the 
tumour because it may come from different cells with 
presumably different genomic alterations, which can be 
detected by sequencing. 
Likewise, circulating cfDNA is much easier to isolate 
than CTCs because it is abundantly present in blood, 
especially in patients with advanced disease[28]. Indeed, 
circulating DNA extraction can be performed following a 
simple protocol that does not exceed 5 h[18]. Once it is 
isolated, PCR, followed by DNA sequencing can be used 
to detect tumor-specific genetic aberrations which may 
also help in the comprehension of tumor dynamics. In 
this issue, droplet digital PCR, together with genome-
wide high throughput sequencing, provide a high 
sensitivity and specificity for detecting mutations[29]. 
These new tools for DNA analysis are also contributing 
to give a more profound insight into the presence and 
role of circulating DNA, among its value as a biomarker. 
CTCs and circulating cfDNA  
It would be reasonable to suspect that tumor cfDNA 
found in the circulation can be released by CTCs. 
However, the discrepancy between the number of CTCs 
and the quantity of circulating DNA discards this theory. 
Considering the average amount of circulating DNA in 
a ml of plasma from advanced-stage cancer patients 
(17 ng) and the amount of DNA contained by a single 
human cells (6 pg), more than 2000 CTCs would be 
required if CTCs were the primary source of circulating 
DNA. Conversely, less than 10 CTCs per 7.5 mL of blood 
are found on average[18]. Therefore, tumor cfDNA might 
come from different regions within the tumor and thus, 
it may better represent tumor genetic heterogeneity. 
This fact, together with its high concentration in blood, 
suggests that circulating DNA might be a better liquid 
biopsy-derived biomarker. In the following section, we 
will focus on the reasons why DNA can be released into 
circulation. 
WHERE DO CIRCULATING NUCLEIC ACIDS 
COMES FROM AND HOW DO THEY 
CIRCULATE IN THE BLOOD STREAM
Depending on how they are released, circulating 
nucleic acids can be found in different forms including 
molecular or macromolecular complex, linked to serum 
proteins or internalized in vesicles such as exosomes or 
microvesicles (Figure 1). In general terms, circulating 
nucleic acids can be either passively released, by 
apoptotic and necrotic cells, or actively released by 
living cells. 
Passive release
During cell-death mechanisms, such as necrosis or apo-
ptosis, both circulating DNA and circulating RNA can be 
liberated into bloodstream by dying or dead cells. 
In necrosis, cellular DNA is incompletely and nons-
pecifically digested. In this condition, a smearing pattern 
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would be observed when DNA is run electrophoretically 
in agarose gel. However, when circulating DNA is an-
alyzed by agarose-gel electrophoresis, a ladder pattern 
is observed. This feature indicates that necrosis is not 
the major source of circulating DNA although it may 
be a possible contributor given the presence of DNA 
fragments ranging from 21 kb to 80 kb in length in blood 
plasma samples[14,30].  
The mentioned ladder pattern is formed by fragments 
ranging from 180 bp to 1000 bp which matches with 
the fragments released from chromatin cleavage into 
nucleosomes, a process that occurs during apoptosis[30]. 
Nucleosome: Nucleosomes are molecular complexes 
that allow DNA stabilization and packing into the nucleus. 
In each nucleosome, 146 bp of double-stranded DNA 
are wound on an octamer of positively-charged proteins 
called histones (H2A, H2B, H3 and H4), through 
electrostatic interaction. Nucleosomes are linked by 10 
to 100 bp of naked DNA, termed as linker DNA. An extra 
histone (H1), which is localized outside the octamer, 
stabilizes the tertiary structure of the chromatin chain[31] 
(Figure 2). Cell death by apoptosis implies the activation 
of a set of caspases that catalyze the hydrolysis of 
cellular components. Some of these caspases (e.g., 
Caspase-3) trigger the activation of endonucleases, 
especially the caspase-activated deoxyribonuclease 
(CAD). Endonucleases cleavage chromatin through 
linker DNA, the most accessible region, generating 
oligo- and mono-nucleosomes that are packed into 
vesicles called apoptotic bodies. Apoptotic bodies are 
subsequently released from the cells and phagocytosed 
by macrophages and dendritic cells. Nevertheless, in 
conditions when higher cellular turnover is required, 
such as inflammation or tumor cell proliferation, this 
process collapses and nucleosomes are liberated into 
circulation[30,31]. Then, cell-free nucleosomes can be 
internalized into cells by crossing plasma membrane and 
penetrating into the nucleus from where it can alter gene 
expression[32].
It is worth noting that the octamer of histones of the 
nucleosome protects DNA molecule from its degradation 
by circulating endonucleases. It also should be noted 
that tumor-derived circulating DNA may be more frag-
mented than DNA derived from healthy cells as recent 




Figure 1  Circulating nucleic acids can be present in different forms. If actively released, circulating nucleic acids can be found inserted in exosomes (1) and 
microvesicles (2), or associated with RNA and lipoproteins forming a complex called the virosome (3). Circulating nucleic acids can be also passively released, mainly 















Figure 2  Chromatin cleavage during apoptosis can be a source of circulating DNA. Circulating DNA can be found in the form of nucleosomes. Each nucleosome 
is composed of 147 of DNA wrapped around an octamer of histones (H2A, H2B, H3 and H4). An extra histone (H1) stabilizes this complex. During apoptosis, CAD 
enzyme cleaves in the naked DNA that links each nucleosome (DNA linker), releasing oligo- or mono-nucleosomes. In cancer, where a higher cellular turnover is 
required, this process can be overloaded and nucleosomes can be secreted into circulation. CAD: Caspase-activated deoxyribonuclease.
García-Casas A et al . Liquid biopsy and the genometastasis theory
382 October 10, 2017|Volume 8|Issue 5|WJCO|www.wjgnet.com
The apoptotic origin is confirmed by the existence 
of circulating mitochondrial DNA (mitDNA). In contrast 
to nuclear DNA, mitDNA is a circular and smaller (16.5 
kb) molecule of DNA, not protected with histones[34]. 
It can be secreted to the circulation during cell death 
(e.g., apoptosis) and mitophagy, which consist on the 
elimination of damaged mitochondria through auto-
phagy[35]. Due to its elevated copy number, circulating 
mitDNA may account for a high proportion of the total 
circulating DNA found in blood. It can be present in 
circulation in both protein-associated and free form[34]. 
Circulating mitDNA measurement and mutation analysis 
has been proposed to diagnose different malignancies 
such as breast tumors or epithelial ovarian cancer and 
hepatocellular or colorectal cancer, respectively[1,36]. 
Active release 
In addition to passive secretion, circulating nucleic acids 
can be actively released through cell-derived vesicles, 
such as exosomes and microvesicles, from living cells. 
The phenomenon of spontaneously released DNA was 
first described in lymphocytes, frog auricles and cultured 
cell lines[37-43]. Like nucleosomes, vesicles protect cell-
free nucleic acids from the circulating nucleases and 
hinder the recognition by the immune system[32]. 
Exosomes: Exosomes are small lipid membrane vesicles 
(50-100 nm) secreted from various cell types including 
dendritic cells, B cells, T cells, tumor cells and epithelial 
cells[44]. Exosomes result from the recycling endosomal 
pathway. During endocytosis, vesicles are generated at the 
plasma membrane and enter into the cell forming early 
endosomes. These early endosomes are transformed 
into late endosomes which then develop multivesicular 
bodies (MVB). MVBs can fused with lysosomes for 
degradation of its content or with the plasma membrane. 
In this last case, internal vesicles are liberated into the 
extracellular space and termed exosomes[45] (Figure 
3). Therefore, exosomes contain membrane and 
cytoplasmic components such as lipids, proteins and RNA 
(mainly mRNA and miRNA). Additionally, the presence 
of single-stranded and double-stranded DNA was further 
demonstrated[46]. 
Furthermore, exosomes are capable to enter 
in recipient cells by either binding to cell surface 
receptors through adhesion molecules or being inter-
nalized through mechanism similar to endocytosis 
and so can act as cellular communicators. What is 
more, these vesicles can travel to distant sites of the 
organism and release the packed biomolecules into 
local and remote cells. Exosomes can bear different 
proteins including transmembrane proteins, such as 
major histocompatibility complex (MHC), and other 
intraluminal proteins and oncoproteins such as mutant 
KRAS[47]. Proteins delivered by exosomes can activate 
or inhibit different signalling pathways, altering cell 
function. For its part, exosomes-derived miRNA can 
modulate gene expression by posttranscriptional re-
gulation. 
Particularly in cancer cells, exosomes secretion 
is usually increased. Tumor-derived (TD) exosomes 
may favour tumor growth by inhibiting apoptosis and 
increasing cellular proliferation. As an example, it 
was demonstrated that exosomes increased cellular 
proliferation in gastric cancer cell lines by activating Akt 








Figure 3  Exosomes and microvesicles can harbour nucleic acids. Exosomes and microvesicles are generated by different pathways. Exosomes derive from 
the recycling endosomal pathway, in which the late endosomes (MVB) merge with the plasma membrane instead of with the lysosome, releasing the exosomes. 
Exosomes encapsulate cytoplasm material such as proteins, RNA or DNA. Microvesicles result from plasma membrane budding, containing cellular components from 
both cell membrane and cell cytoplasm, including nucleic acids. MVB: Multivesicular bodies.
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TD exosomes can also facilitate cancer invasion and 
metastasis by regulating stromal cells, remodelling the 
extracellular matrix and stimulating angiogenesis[47,49]. 
Regarding to nucleic acids, the presence of mRNAs, 
miRNAs and DNA highlights the role of exosomes as 
carriers of genetic information too. Indeed, the role of 
exosome-derived miRNA has been widely demonstrated. 
Depending on its target gene, miRNA can act either as a 
tumor suppressor or as a tumor enhancer. For instance, 
miR-198 has been demonstrated to be released by 
T-lymphoblast exosomes performing a tumor suppressor 
role in lung, liver and colorectal cancer[50-55]. Conversely, 
other miRNAs favour tumor progression such as miR-21, 
which can also be secreted through exosomes[56,57]. It 
should be considered that exosomes generally carry 
more than one kind of miRNA, so its effects depend on 
the combination of miRNAs presented[58]. 
Microvesicles: Microvesicles emerge from plasma 
membrane budding and the following fission of the 
vesicles from the plasma membrane. They have a larger 
size (100-1000 nm) than exosomes and membrane 
composition is more similar to that of plasma membrane 
than exosome membrane composition (Figure 3). Thus, 
tumor-derived microvesicles constitute a representation 
of the tumor proteomic signature. Microvesicles can be 
secreted by different cell types including hematopoietic 
cells, endothelial cells, mesenchymal stem cells and 
cancer cells[59]. It has to be taken into consideration 
that, despite their differences, the terms exosomes and 
microvesicles are usually interchanged. Moreover, in 
most studies, vesicles are obtained by approaches that 
cannot discriminate both types of vesicles and so it may 
be difficult to classify published information according to 
each type. 
As well as exosomes, microvesicles are key elements 
in cell-to cell communication, modulating the recipient 
cell phenotype. For instance, it has been shown that 
cultured hematopoietic progenitor cells can be repro-
grammed by microvesicles derived from embryonic stem 
cells. In fact, these microvesicles contained mRNA for 
several pluripotent transcription factors demonstrating 
an additional mechanism of horizontal transfer of genetic 
material[60]. 
In cancer scenario, microvesicles from tumor and 
non-tumor cells can also be secreted to transfer miRNA 
and other oncogenic proteins to facilitate invasion and 
tumor growth. Likewise, it was reported that tumor-
derived microvesicles carrying surface determinants of 
tumor cells, like chemokine receptors, and mRNA for 
growth factors, such as vascular endothelial growth 
factor (VEGF) or hepatocyte growth factor (HGF), were 
able to internalize in monocytes and so, change its 
phenotype and biology activity[61]. Furthermore, it was 
also published that tumor-associated macrophages 
can secrete microvesicles containing miRNA that can 
promote breast tumor cell invasiveness[62]. 
Virtosomes: The existence of virtosomes was first 
described by Stroun and Gahan[63]. The virtosome is a 
macromolecular complex formed by newly synthesized 
DNA and RNA associated with lipoproteins, which is 
spontaneously released from living cells. To form this 
structure, newly DNA is synthesised in the nucleus 
and then transferred to the cytosol. In cytosol, DNA 
associates with a lipoprotein, which serves as a pro-
tector from nuclease digestion, and before leaving 
the cell, an RNA molecule is attached to the complex. 
The complex can exit the cell in an energy-dependent 
way and entering other cells by mechanism not well 
understood[63]. 
Viral nucleic acids: Viral DNA as well as viral RNA can 
be found in plasma and serum from patients[30]. Given 
the relation between some viral infections and particular 
malignancies, detection of viral DNA might be used as a 
biomarker for certain neoplastic disease. As an example, 
cell-free DNA from Epstein-Barr virus (EBV) serves as 
diagnostic and prognostic marker for nasopharyngeal 
carcinoma[64].
Nucleic acids can be attached to cell surface 
cfDNA and RNA can also be found attached to the 
exterior part of the plasma membrane from where 
they can be detached and released into circulation. 
DNA is usually found in the cell surface of leucocytes 
and erythrocytes and can be internalized by receptor 
recognition or remain associated with the surface[30].  
GATHERING PIECES
Liquid biopsy has been commonly proposed as a tool 
for cancer diagnostic, characterisation and prognostic 
in patients as both CTCs and cfNA provide relevant 
information from the tumor. Nonetheless, very much 
attention has been paid for this practical application 
without taking full account of the possible biological 
roles of cfNA in blood. Although it is known how 
circulating nucleic acids can be presented in blood (as 
it has been described), its function in this location is 
still controversial. Considering the above commented 
discrepancy between CTCs number and cfDNA quantity 
as well as the active mechanisms of cfNA release, 
cfNA presence in blood does not appear to be a mere 
coincidence. What is more, many evidences point to 
cfNA as a key driver of metastasis, which is the essence 
of the theory of genometastasis. 
GENOMETASTASIS: A PUTATIVE 
MECHANISM INVOLVED IN THE ORIGIN 
OF METASTASIS
Metastasis is an enormously complex process that 
remains to be a major problem in the management of 
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cancer. The metastatic properties of tumor cells were 
extensively investigated from 1970s, although so much 
earlier (as soon as 1889) it was proposed the “seed 
an soil” theory that today is still alive and even under 
constant reformulation (e.g.,[65])
During the seventies, some theories were proposed, 
such as that most primary tumor cells have a low 
metastatic potential, and that during later stages of 
tumorigenesis rare cells acquire metastatic capacity 
through additional somatic mutations  (reviewed in[66]). 
This suggested mechanism had contrary evidence in 
other studies that concluded that metastases are a 
random representation of disseminated tumor cells, all 
of which have the ability to form a metastasis[66]. On the 
whole, it might be said that the discussion of “dynamic 
heterogeneity” models vs “clonal dominance” theories 
prevailed during two decades, always under the 
premise of a circulatory view of cancer progression. In 
fact, nowadays, many authors appears to not conceive 
any other way, as showed in the recent literature, e.g., 
“Metastasis is the consequence of a cancer cell that 
disperses from the primary tumor, travels throughout 
the body, and invades and colonizes a distant site”[65].
This view does not explain some questions such as 
the lack of correlation between the sites of development 
of metastasis and the anatomic vascular filters[67]. Several 
million cells per gram of tumor can be shed daily into the 
lymphatic system or bloodstream. However, insufficient 
data exists to quantify the fraction of shed tumor cells 
that successfully seed secondary tissues. Moreover, 
the fate of blood borne tumor cells is controversial 
and many experimental evidence are contradictory: 
Whereas in some models most circulating cells die, in 
others most survive and extravasate. Nevertheless, all 
studies show that most cells entering the vasculature 
fail to form macroscopic foci at distant sites (reviewed 
in[68]).  On the other hand, an unquestionable fact is that 
the identification and characterization of CTC require 
extremely sensitive and specific analytical methods, 
much more than detection of cell-free tumor DNA.
In connection with the circulatory theory, surgical 
maneuvers for tumor resection (particularly, gastro-
intestinal tumors) have classically been designed to avoid 
blood dissemination of cancer cells, which hypothetically 
results in a lower risk of recurrence and metastasis 
(reviewed in[69]). However, benefits of such procedures 
have not been fully demonstrated yet. At late 1990s, our 
group challenged that technical axiom-not sufficiently 
supported-, and performed a study in colorectal cancer 
patients that showed that the use of no-touch isolation 
techniques in colorectal cancer was not justified, based 
on lack of evidence indicating the detachment of cells 
from the tumor at surgery[70]. Apart from the clinical 
discussion (which has not been finished yet), the fact 
was that circulation of tumor cells appeared to have 
lesser value than attributed. In parallel, the evidence of 
high levels of cell-free nucleic acids in plasma of cancer 
patients and tumor-bearing animals led us to examine 
the biological role of such molecules[1,29,71]. Firstly in 
cancer models using immunocompetent animals and 
later in clinical studies with colon cancer patients, we 
demonstrated the biological feasibility of gene transfer 
and of the transformation of cells by cell-free tumor-
derived nucleic acids in the plasma[41,72,73]. In the light 
of such results, we proposed that cell-free nucleic acids 
in the plasma participate in tumorigenesis and the 
development of metastases via transfection-like uptake 
of such nucleic acids by susceptible cells. This putative 
phenomenon was named as “genometastasis” (Figure 4). 
Albeit, at first, some authors exhibited more criticism 
than enthusiasm for this hypothesis[74], later experimental 
evidence supported the existence of the genometastasis. 
Moreover, the assays that substantiated this theory were 
repeated and enlarged by other authors, who confirmed 
our results[75-78].
Consistently with our theory, recently Mittra et al[79] 
have asserted that circulating nucleic acids, far from 
being biologically inert particles, have significant dele-
terious functions in the host. According with their 
results, they concluded that circulating nucleic acids are 
ubiquitous and continuously arising, and freely can enter 
healthy cells integrate into their genomes, inflicting 
repeated damage to the somatic DNA. Moreover, the 
authors have suggested that the somatic genome may 
not be stable, but rather remains in a state of turmoil 
characterized by dsDNA breaks, genomic instability 
and apoptosis affected by integration of circulating 
DNA. These events may lead to deletions, duplications 
and rearrangements causing DNA mosaicism[79]. Once 
demonstrated the existence of this phenomena and 
connecting all previous results, it would be even naive 
to think that progression of cancer is not related to 
triggering genetic events and consequent genomic 
rearrangements.
Nonetheless, despite the soundness of results, some 
authors were still showing their reticence to accept the 
genometastasis as a feasible mechanism for metastasis, 
arguing mainly that such theory is not able to explain 
the tropism of metastasis[80]. In our opinion, this is an 
erroneous assessment perhaps motivated by a partial 
view of the phenomenon that we described, because, 
precisely, in both own and other authors’ studies, it was 
shown that not all kind of cells were transformed by 
plasma[73,75,76]. Our model is, not only incompatible with 
the idea of specific tropism for metastasis, but it is really 
proper to search tropism mechanism.
Mittra et al[79] clearly demonstrated that cellular/
nuclear uptake of DNA is energy dependent and 
requires an active metabolic machinery of the recipient 
cells, which might be a first selection. However, it is 
possible that the key is not only in the characteristics 
of susceptible cells (“soil”), but also in the particles 
circulating in the transforming plasma (“seed”). In 
fact, there is an increasing stream of studies about the 
potential of extracellular vesicles on induction of cellular 
transformation and most of those observations are fully 
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consistent with the theory of genometastasis[81-83].
LOOK TO THE FUTURE: TREATMENTS 
BASED ON THE GENOMETASTASIS 
PHENOMENON
Traditionally, treatments directed to prevent metastasis 
have been based on the use of cytotoxic substances 
that avoid circulation, homing and reproduction of 
malignant cells. If we assume that circulating nucleic 
acids in cancer patients have a role in the production of 
metastasis, a new scenario can be opened up. We can 
imagine a variety of strategies for interfering with these 
circulating nucleic acids either during their travel or 
during the horizontal transfer at the target organ. 
Perhaps, the most immediate approach appears to 
be the use of enzymes to degrade circulating nucleic 
acids. The idea of enzymes-based therapies for cancer 
hovered since four decades ago[84], and in the last years, 
some convincing approaches have been reported. For 
example, Trejo-Becerril et al[85] have reported that 
systemic treatment with DNAse I and a protease mix 
in rats decreased DNA and proteins from serum and 
had antitumor effects. Interestingly, Patutina et al[86] 
have reported that tumor-bearing animals treated 
with RNase A and DNase I had a general systemic 
and immunomodulatory effect that led to a drastic 
suppression of metastasis development. Undoubtedly, 
those results support the role of the genometastasis 
phenomenon in the development of metastasis and 
encourage deepening.
Other potential therapeutic approach might be based 
on the use of potentially transfecting particles charged 
by “good sequences” of nucleic acids. It has not been 
enough tested but, theoretically, it is possible that such 
particles promote a “competitive” effect with cell-free 
tumor nucleic acids and, then, avoiding metastasis. In 
this line, virtosomes (i.e., the mentioned DNA-RNA-
lipoprotein complex) might constitute a useful tool. These 
particles are spontaneously released from healthy human, 
other mammalian, avian, amphibian and plant cells in a 
regulated and energy-dependent manner[63]. Likewise, 
these released virtosomes have been demonstrated to 
enter other cells[87-89]. More importantly, the biology of the 
recipient cells may be also modified if virtosomes come 
from a different cell type. Experiments with virtosomes in 
an immunocompetent animal model of colorectal cancer, 
showed a virtosomal effect in blocking cell multiplication in 
both in vitro and in vivo studies, resulting in a scape from 
inhibition at times after inhibition initiation. These results 
could indicate the existence of a response derived from 
the initiation of an immune reaction[90]. 
In other way, some previous studies have suggested 
the possibility of silencing these circulating oncogenic 
signals through RNA interference. As an example, 
the use of some micro-RNA can determine a novel 
regulatory pathway in KRAS-driven cancers, which offers 
a potential therapeutic target for their eradication[91], 
if this microRNAs are harboured by particles such as 
virtosomes or exosomes. 
Indeed, a lot of strategies can be suggested in order 
to interfere with the horizontal transfer mechanism, 
responsible for the transformation of healthy and normal 
cell into malignant cell. Nonetheless, as happens with 
all new paradigms, lots of further lines of research are 
required in this field. 
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